Literature DB >> 12161533

p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol.

Zhijian Gao1, Hiroya Matsuo, Satoshi Nakago, Osamu Kurachi, Takeshi Maruo.   

Abstract

p53 protein, a tumor suppressor gene product, has been reported to play a crucial role in suppressing the growth of a variety of cancer cells. However, little information is currently available regarding the content of p53 protein in human leiomyomas. The present study was conducted to elucidate the p53 protein content in human leiomyomas and its regulation by sex steroid hormones. The content of p53 protein in leiomyomas was examined by immunohistochemical staining and Western blot analysis in comparison with that in the adjacent normal myometrium or leiomyoma specimens from GnRH agonist-treated patients. In addition, isolated human leiomyoma cells were subcultured in phenol red-free DMEM supplemented with 10% FBS for 120 h and then stepped down to serum-free conditions for an additional 72 h in the absence or presence of 17 beta-estradiol (E2; 10 ng/ml), progesterone (P4; 100 ng/ml), or E2 (10 ng/ml) plus P4 (100 ng/ml). The effects of sex steroids on p53 protein content in cultured leiomyoma cells were also assessed by Western immunoblot analysis. Immunohistochemical staining and Western blot analysis revealed that p53 protein content was highest in leiomyomas treated with GnRH agonist for 16 wk, lower in leiomyomas in the secretory, P4-dominated phase, and lowest in leiomyomas in the proliferative, E2-dominated phase of the menstrual cycle. There was no difference in p53 content between leiomyomas and the adjacent normal myometrium. Western blot analysis of cultured leiomyoma cell extracts revealed that E2 treatment significantly decreased p53 protein content compared with the control cultures, whereas either P4 treatment or combined treatment with E2 and P4 did not affect p53 protein content in cultured leiomyoma cells. The concentrations of sex steroid hormones used were within the physiological tissue concentrations in leiomyomas and myometrium described earlier. The present study suggests that E2 down-regulates p53 protein content, whereas P4 is ineffective in those cells. The E2-induced decrease in p53 protein content in leiomyoma cells leads us to propose that E2 may regulate human leiomyoma growth in part by down-regulating p53 tumor suppressor protein content in those cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161533     DOI: 10.1210/jcem.87.8.8711

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.

Authors:  Zhijian Gao; Xiaoyin Xu; Bruce McClane; Qing Zeng; Babak Litkouhi; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

2.  Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model.

Authors:  M H Hassan; H Fouad; S Bahashwan; A Al-Hendy
Journal:  Hum Reprod       Date:  2011-09-06       Impact factor: 6.918

3.  Expression of p53 and p21(WAF-1), apoptosis, and proliferation of smooth muscle cells in normal myometrium during the menstrual cycle: implication of DNA damage and repair for leiomyoma development.

Authors:  Ayako Suzuki; Masatoshi Kariya; Noriomi Matsumura; Tsukasa Baba; Haruhiko Yagi; Masaki Mandai; Ikuo Konishi; Shingo Fujii
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

4.  Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model.

Authors:  Memy H Hassan; Salama A Salama; Dong Zhang; Hossam M M Arafa; Farid M A Hamada; Hala Fouad; Cheryl C Walker; Ayman Al-Hendy
Journal:  Fertil Steril       Date:  2009-01-14       Impact factor: 7.329

5.  Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium.

Authors:  Dominique N Markowski; Burkhard M Helmke; Arlo Radtke; Jennifer Froeb; Gazanfer Belge; Sabine Bartnitzke; Werner Wosniok; Iris Czybulka-Jachertz; Ulrich Deichert; Jörn Bullerdiek
Journal:  BMC Womens Health       Date:  2012-01-10       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.